New therapy with XLQ^® to suppress chronic prostatitis through its anti-inflammatory and antioxidative activities

Area of Science:

• Urology
• Pharmacology
• Immunology

Background:

• Chronic prostatitis is a prevalent urological condition with unclear etiology and limited effective treatments.
• Investigating novel therapeutic agents is crucial for managing chronic prostatitis.

Purpose of the Study:

• To evaluate the therapeutic potential of XLQ® in a rat model of chronic nonbacterial prostatitis.
• To elucidate the anti-inflammatory and antioxidant mechanisms of XLQ® in this condition.

Main Methods:

• A complete Freund's adjuvant-induced rat model of chronic prostatitis was utilized.
• Rats were treated with XLQ® or a vehicle for four weeks, followed by prostate and blood sample analysis.
• Histopathological examination, cytokine expression analysis, antioxidant enzyme activity assays, and signaling pathway assessments were performed.

Main Results:

• XLQ® treatment significantly reduced prostate index and ameliorated histopathological changes.
• XLQ® suppressed infiltration of immune cells (CD3+, CD45+) and downregulated pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, etc.).
• XLQ® enhanced antioxidant enzyme activities, reduced lipid peroxidation, and inhibited NF-κB and p38 MAPK signaling pathways.

Conclusions:

• XLQ® exhibits significant anti-inflammatory and antioxidative effects in chronic prostatitis.
• These properties suggest XLQ® could be developed into an effective and safe therapeutic option for chronic prostatitis.
• The study highlights XLQ®'s potential to modulate key inflammatory and oxidative stress pathways involved in prostatitis.